Nicholas Goldner

Company: Resistance Bio

Job title: Chief Executive Officer and Co-Founder

Seminars:

Leveraging ENCER Cancer Models to Predict Clinical Trial Outcomes of Novel Mono & Combination Therapies 9:30 am

Our proprietary ENCER (ENvironmental CEllular Reprogramming) cancer models can predict clinical trial outcomes before the clinic. We capture multi-omic data longitudinally over months, aiding in identifying novel biomarkers and targets which can be used in mono or combination therapy.  ENCER can identify the most effective modality for drugging your target of interest with fewer off-target…Read more

day: Conference Day One